Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium‐chain acyl‐CoA dehydrogenase deficiency

Medium‐chain acyl‐CoA dehydrogenase deficiency (MCADD) is the most frequent inherited defect of fatty acid oxidation, with a significant morbidity and mortality in undiagnosed patients. Adverse outcomes can effectively be prevented by avoiding metabolic stress and following simple dietary measures. Therefore, prospective newborn screening (NBS) is being proposed for this condition. However, technical validation of MCADD population screening and assessment of its overall benefit require broadening of the as‐yet‐scarce knowledge of the MCADD genetic heterogeneity unraveled by NBS and its phenotypic consequences. Here, we describe the entire spectrum of sequence variations occurring in newborns with MCADD in the population of Bavaria, Germany, in relation to the biochemical phenotype. Among 524,287 newborns, we identified 62 cases of MCADD, indicating a birth incidence of 1 in 8,456. In all of the 57 newborns available for analysis, two alterations within the MCADD gene (ACADM) were identified. The most prevalent alteration c.985A>G (Lys329Glu) occurred in 27 (47%) newborns in the homozygous and in 18 (32%) in the heterozygous state (63% of defective alleles). The mild folding variant c.199T>C (Tyr67His) was identified in nine individuals, six of them being compound heterozygous with c.985A>G (Lys329Glu). Neither of the prevalent alterations were found in the remaining nine newborns. A total of 18 sequence variations were identified; 13 of them were novel: eight missense mutations, one nonsense mutation, two splice variants, and two small deletions. The remaining five were previously reported in MCADD patients. The ACADM heterogeneity uncovered was larger as anticipated from previous c.985A>G (Lys329Glu) carrier screening data. In addition, we show that MCADD appears to occur as frequently in Turkish newborns as in the native German population. Our data validate that biochemical NBS for MCADD is a highly specific procedure for disease detection, with the identification of a significant share of milder biochemical phenotypes, such as c.199T>C (Tyr67His). These show statistically lower acylcarnitine markers, allowing us to distinguish subgroups within the spectrum of ACADM sequence variations that correlate to biochemical MCADD disease expression. Our data might provide technical and medical guidance for decision making in the worldwide efforts to introduce MCADD population screening. Hum Mutat 25:443–452, 2005. © 2005 Wiley‐Liss, Inc.

[1]  Bernhard Liebl,et al.  Expanded newborn screening in Bavaria: tracking to achieve requested repeat testing. , 2002, Preventive medicine.

[2]  I Knudsen,et al.  Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. , 2001, American journal of human genetics.

[3]  H. Dietz,et al.  Nonsense-mediated mRNA decay in health and disease. , 1999, Human molecular genetics.

[4]  S. Packman,et al.  The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype? , 1997, Human molecular genetics.

[5]  D. Marsden,et al.  Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. , 2001, Clinical chemistry.

[6]  A. A. Roscher,et al.  Erweiterung des Neugeborenenscreenings durch Tandemmassenspektrometrie , 2001, Monatsschrift Kinderheilkunde.

[7]  M. Culbertson,et al.  RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. , 1999, Trends in genetics : TIG.

[8]  K. Tanaka,et al.  Molecular survey of a prevalent mutation, 985A-to-G transition, and identification of five infrequent mutations in the medium-chain Acyl-CoA dehydrogenase (MCAD) gene in 55 patients with MCAD deficiency. , 1991, American journal of human genetics.

[9]  K. Tanaka,et al.  Mutations in the medium chain acyl‐CoA dehydrogenase (MCAD) gene , 1992, Human mutation.

[10]  H. Eiberg,et al.  A survey of the newborn populations in Belgium, Germany, Poland, Czech Republic, Hungary, Bulgaria, Spain, Turkey, and Japan for the G985 variant allele with haplotype analysis at the medium chain Acyl-CoA dehydrogenase gene locus: clinical and evolutionary consideration. , 1997 .

[11]  B. Wilcken,et al.  Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275 000 babies , 2001, Archives of disease in childhood. Fetal and neonatal edition.

[12]  G. Finocchiaro,et al.  Molecular cloning and nucleotide sequence of cDNA encoding the entire precursor of rat liver medium chain acyl coenzyme A dehydrogenase. , 1987, The Journal of biological chemistry.

[13]  P. Clayton,et al.  Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis , 1999, Archives of disease in childhood.

[14]  R. Wanders,et al.  Molecular and functional characterisation of mild MCAD deficiency , 2001, Human Genetics.

[15]  J. Leonard,et al.  Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK , 1998, Archives of disease in childhood.

[16]  H. Möller,et al.  Normal Clinical Outcome in Untreated Subjects with Mild Hyperphenylalaninemia , 2001, Pediatric Research.

[17]  L. Bolund,et al.  Specific diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in dried blood spots by a polymerase chain reaction (PCR) assay detecting a point-mutation (G985) in the MCAD gene. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[18]  C. Zhou,et al.  Identification of a novel mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency. , 2000, Molecular genetics and metabolism.

[19]  N. Bosshard,et al.  Partial deficiency of galactose-1-phosphate uridyltransferase , 2005, European Journal of Pediatrics.

[20]  B. Wilcken,et al.  Screening newborns for inborn errors of metabolism by tandem mass spectrometry. , 2003, The New England journal of medicine.

[21]  H. Levy,et al.  Genetic screening of newborns. , 2003, Annual review of genomics and human genetics.

[22]  C R Scriver,et al.  Proof of “disease causing” mutation , 1998, Human mutation.

[23]  Bernhard Liebl,et al.  Very high compliance in an expanded MS-MS-based newborn screening program despite written parental consent. , 2002, Preventive medicine.

[24]  H. Eiberg,et al.  A Survey of the Newborn Populations in Belgium, Germany, Poland, Czech Republic, Hungary, Bulgaria, Spain, Turkey, and Japan for the G985 Variant Allele with Haplotype Analysis at the Medium Chain Acyl-CoA , 1997, Pediatric Research.

[25]  Martin Lindner,et al.  Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. , 2003, Pediatrics.

[26]  D. Chace,et al.  Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. , 2003, Clinical chemistry.

[27]  C. Roe,et al.  Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. , 1994, The Journal of pediatrics.

[28]  E. Hoffman,et al.  Medium Chain Acyl-CoA Dehydrogenase Deficiency in Pennsylvania: Neonatal Screening Shows High Incidence and Unexpected Mutation Frequencies , 1995, Pediatric Research.

[29]  H. Troxler,et al.  Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. , 2001, Clinical chemistry.

[30]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .